Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675362 | 0.95 | USP2 (0.50) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL2904258 | 0.93 | MEN1 (0.50) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL8242595 | 0.86 | USP2 (0.61) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL20046379 | 0.86 | CNR1 (0.44) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL698803 | 0.85 | USP2 (0.69) | USP2SMN1; SMN2HPGDEPHX2ALDH1A1 | |
| SCHEMBL18294 | 0.85 | USP2 (0.69) | USP2SMN1; SMN2HPGDEPHX2ALDH1A1 | |
| SCHEMBL2616174 | 0.85 | USP2 (0.51) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL5573083 | 0.85 | USP2 (0.55) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL20353659 | 0.84 | CYP2D6 (0.48) | USP2SMN1; SMN2HPGDEPHX2ALDH1A1 | |
| SCHEMBL27345518 | 0.84 | GPR119 (0.56) | USP2SMN1; SMN2HPGDRECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108675959-B | Deuterated enrofloxacin-d5Preparation method of (1) | 雅安职业技术学院 | 2022-02-25 | — | — | CN | claimed |
| CN-119977911-A | Cationic lipid compound and preparation method, composition and application thereof | 羿美诚健(上海)生物医药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024132278-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | UNIVERSITÄT REGENSBURG (DE) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389223-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2024-06-26 | — | — | EP | disclosed |
| EP-4389223-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-11814370-B2 | Deuterated N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-14 | — | — | US | disclosed |
| US-11793821-B2 | Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2023-10-24 | — | — | US | disclosed |
| US-11780854-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2023-10-10 | — | — | US | disclosed |
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| WO-2023118085-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2023-06-29 | — | — | WO | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070238727-A1 | 5-Substituted 1-Phenyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones and Analogs as Anti-Virals | TIBOTEC BVBA (BE) | 2007-10-11 | — | — | US | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| US-7157473-B2 | Pyridyl substituted heterocycles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| WO-2006042103-A2 | REVERSIBLE INHIBITORS OF CATHEPSIN B | AXYS PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1289972-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096323-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| US-5932737-A | BENZOFURANYL- OR BENZOTHIENYL-TERMINATED | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-03 | — | — | US | disclosed |
| EP-0796270-A2 | PEPTIDE COMPOUNDS FOR PREVENTION AND/OR TREATMENT OF NO-MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-24 | — | — | EP | disclosed |
| WO-1996016981-A2 | PEPTIDE COMPOUNDS FOR PREVENTION AND/OR TREATMENT OF NO-MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793821-B2 | Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA6, CHRNA5 | USP2 2882/4885SMN1; SMN2 2477/4885CHRM2 15/4885 |
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | EGLN3, EGLN2, EGLN1 | USP2 133/4885SMN1; SMN2 4522/4885CHRM2 4882/4885 |
| US-20070238727-A1 | 5-Substituted 1-Phenyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones and Analogs as Anti-Virals | NR5A2, NR5A1, NR4A1 | USP2 4332/4885SMN1; SMN2 3718/4885CHRM2 535/4885 |
| US-11814370-B2 | Deuterated N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide | HTR5A, HTR2C, HTR6 | USP2 3294/4885SMN1; SMN2 1222/4885CHRM2 428/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | USP2 4330/4885SMN1; SMN2 3077/4885CHRM2 151/4885 |
| US-11780854-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | EGLN2, EGLN3, EGLN1 | USP2 194/4885SMN1; SMN2 3950/4885CHRM2 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.